References
1. IDF Diabetes Atlas. 9th ed. International Diabetes Federation, 2019. URL: https://www.diabetesatlas.org/en/ (date of access May 08, 2020)
2. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (2): 104-12. DOI: 10.14341/DM2004116-17 (in Russian)
3. Dedov I.I., Shestakova M.V., Mayorov A.Y., et al. (eds). Standards of specialized diabetes care. 9th ed. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (S 1-1): 1-144. DOI: 10.14341/DM221S 1 (in Russian)
4. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41 (2): 255-23. DOI: 10.1093/eurheartj/ehz486
5. Shah A.D., Langenberg C., Rapsomaniki E., Denaxas S., Pujades-Rodriguez M., Gale C.P., et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 19 million people. Lancet Diabetes Endocrinol. 2015; 3 (2): 105-13. DOI: 10.1016/S 2213-8587(14)70219-0
6. Petunina N.A., Trukhin I.V., Trukhina L.V., Sizova Z.M., Zakharova V.L. Heart failure and diabetes mellitus: insight into comorbidity. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (1): 79-87. DOI: 10.14341/ DM9784 (in Russian)
7. Bell DSH. Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003; 26 (8): 2433-41. DOI: 10.2337/diacare.26.8.2433
8. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34 (1): 29-34. DOI: 10.1016/0002-9149(74)90089-7
9. Shestakova M.V. DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (6): 592-601. DOI: 10.14341/DM10289 (in Russian)
10. Nichols G.A., Gullion C.M., Koro C.E., et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27 (8): 1879-84. DOI: 10.2337/diacare.27.8.1879
11. Faden G., et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013; 101: 309-16.
12. Boonman-de Winter L.J., et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55: 2154-62. DOI: 10.1007/s00125-012-2579-0
13. Wu B., et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns - NHANES 2007-2012. Article and supplementary tables. BMJ Open Diabetes Res Care. 2016; 4 (1): e000154.
14. Shamkhalova M.S., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Shestakova M.V., Dedov I.I. Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal Diabetes Register (2013-2016). Sakharniy diabet [Diabetes Mellitus]. 2018; 21 (3): 160-9. DOI: 10.14341/DM9392 (in Russian)
15. Foley R.N., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 16: 489-95.
16. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.A., Isakov M.A. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Sakharniy diabet [Diabetes Mellitus]. 2018; 21 (3): 144-59. DOI: 10.14341/DM9686. (in Russian)
17. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A. Atlas of the diabetes registry of the Russian Federation, status 2018. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (S 2-2): 4-61. (in Russian)
18. Bertoni A.G., et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004; 27: 699-703. DOI: 10.2337/diacare.27.3.699
19. Kato M. The concept of heart failure: chronic diseases accompanied by an attack of acute exacerbation. In: Sato N. (ed.). Therapeutic Strategies for Heart Failure. Tokyo, Japan: Springer, 2018: 1-15.
20. Tuppin P., et al. Two-year outcome of patients after a first hospitalization for heart failure: A national observational study. Arch Cardiovasc Dis. 2014; 107: 158-68. DOI: 10.1016/j.acvd.2014.01.012
21. White W.B., et al. Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Diabetes Care. 2016; 39 (7): 1267-73. DOI: 10.2337/dc16-0303
22. Pharmacologic approaches to glycemic management: standards of medical care in diabetes - 2020. Diabetes Care. 2020; 43 (1): S 98-110. DOI: 10.2337/dc20-S 009
23. Buse J.B., et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020; 63: 221-8. DOI: 10.2337/dci19-0066
24. Scirica B.M., et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2015; 132: e198.
25. Seferovic P., et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur Heart Fail. 2018; 20: 853-72. DOI: 10.1002/ejhf.1170
26. White W.B., et al. DPP-4 inhibitors and risk of heart failure EXAMINE. N Engl J Med. 2013; 369: 1327-35. DOI: 10.1016/S 0140-6736(15)60037-X
27. Green J.B., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232-42. DOI: 10.1056/NE-JMoa1501352
28. Rosenstock J., et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabet Vasc Dis Res. 2013; 10: 289-301. DOI: 10.1177/1479164112475102
29. Rosenstock J., et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA. 2019; 321 (1): 69-79. DOI: 10.1001/jama.2018.18269
30. Kristensen S.L., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019; 7: 776-85. URL: 10.1016/S 2213-8587(19)30249-9
31. Zelniker T.A., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393 (10 166): 31-9. DOI: 10.1016/ S 0140-6736(18)32590-X
32. Verma S., Jdni P., Mazer C.D. Comment Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet. 2019; 393 (10 166): 3-5. DOI: 10.1016/S 0140-6736(18)32824-1
33. Wiviott S.D., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-57. DOI: 10.1056/NE-JMoa1812389
34. Zinman B., et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™), Cardiovasc Diabetol. 2014; 13: 102. DOI: 10.1186/1475-2840-13-102
35. Neal M.B., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644-57. DOI: 10.1056/NE-JMoa1611925
36. Forxiga. Instructions for medical use (film-coated tablets, 5 mg, 10 mg). Registration certificate LP-002596 from 24.12.2019. (in Russian)
37. McMurray J.J.V., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008. DOI: 10.1056/NEJMoa1911303
38. Petrie M.C., et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020; 323 (14): 1353-68. DOI: 10.1001/ jama.2020.1906
39. Verma S., McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61 (10): 2108-17. DOI: 10.1007/s00125-018-4670-7
40. Bertero E., Prates Roma L., Ameri P., et al. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018; 114 (1): 12-8. DOI: 10.1093/cvr/cvx149
41. Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Med. 2017; 130 (6S): S 30-9. DOI: 10.1016/j.amjmed.2017.04.009
42. Persson F., et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018; 20 (2): 344-51. DOI: 10.1111/dom.13077